Kodiak Sciences Inc., a Palo Alto, CA-based development-stage biopharmaceutical company specializing in novel therapeutics to treat high prevalence ophthalmic diseases, completed a $33m mezzanine private financing of convertible notes.
Backers included Perceptive Advisors and ArrowMark Partners, which joined existing investors.
The company intends to use the proceeds from the financing to advance the development of KSI-301, its lead product candidate.
Led by Victor Perlroth, M.D., CEO, Kodiak Sciences is advancing KSI-301, an anti-VEGF therapy for wet age-related macular degeneration and diabetic retinopathy.
FinSMEs
27/04/2018